CaReMe is a collaboration between the British Cardiovascular Society, the Renal Association and the Association of British Clinical Diabetologists. The three professional Societies, along with the Primary Care Cardiovascular Society and the Primary Care Diabetes Society have formed the Cardio-Renal-Metabolic (CaReMe) partnership with the aim of improving the management of patients with diabetes, cardiovascular and renal disease.

Latest Updates

24 November 2020 - HF Algorithm Modified from Management algorithm for NICE guideline “Chronic Heart Failure in Adults: diagnosis & management”

6 November 2020 - Leaflet and booklet developed to explain to people starting SGLT-2 inhibitors what they are, the possible side effects and when to seek help

7 September 2020 - Guide for non-diabetes specialist physicians and primary care teams for cardiovascular risk optimisationin patients with Type 2 diabetes and atherosclerotic cardiovascular disease. (coronary artery disease, peripheral arterial disease, cerebrovascular disease)

The CaReMe Webinar took place on 16 July 2020. 2 CPD points are available only to those who registered and attended the live event.


  • Welcome & introduction by the Chair (Prof Martin Cowie)
  • Diabetes, cardiac and renal disease - adding insult to injury (Dr Peter Winocour)
  • Diabetes and Cardiovascular outcome trials (Dr Dipesh Patel)
  • Contemporary management of heart failure (Dr Simon Williams)
  • Avoiding Acute Kidney Injury in heart failure (Dr Debasish Banerjee)
  • Panel discussion and Q&A

CaReMe Partnership

CaReMe Webinar

Featuring presentations from key opinion leaders covering the interface between heart failure, renal disease and diabetes including the latest clinical trial data.

The Boehringer Ingelheim and Lilly Diabetes Alliance (The Alliance) have sponsored this webinar by contributing to the costs of audio-visual provision and webinar hosting. The Alliance has had no input into the agenda topics, meeting content or speaker selection. SGLT2 inhibitors are not licensed in the UK to treat heart failure.

CaReMe Partnership